Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Merus N.V. (Nasdaq: MRUS), a biotechnology company specializing in innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Bill Lundberg, M.D., will engage in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of the Merus website, where the presentation recording will remain available for a time following the event.
Merus N.V. (Nasdaq: MRUS), una società biotecnologica specializzata in anticorpi multispecifici innovativi e coniugati di farmaci anticorpali (Biclonics®, Triclonics® e ADClonics®), ha annunciato la sua partecipazione alla 24a Conferenza Virtuale Annuale di Needham sulla Salute.
Il Presidente e CEO dell'azienda, Bill Lundberg, M.D., parteciperà a una chiacchierata informale il martedì 8 aprile 2025, alle 8:45 a.m. ET. Gli investitori e le parti interessate possono accedere alla diretta tramite la sezione Investitori del sito web di Merus, dove la registrazione della presentazione rimarrà disponibile per un certo periodo dopo l'evento.
Merus N.V. (Nasdaq: MRUS), una empresa biotecnológica especializada en anticuerpos multispecíficos innovadores y conjugados de fármacos anticuerpos (Biclonics®, Triclonics® y ADClonics®), ha anunciado su participación en la 24ª Conferencia Virtual Anual de Needham sobre Salud.
El Presidente y CEO de la empresa, Bill Lundberg, M.D., participará en una charla informal el martes 8 de abril de 2025, a las 8:45 a.m. ET. Los inversionistas y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Inversores del sitio web de Merus, donde la grabación de la presentación estará disponible por un tiempo después del evento.
Merus N.V. (Nasdaq: MRUS)는 혁신적인 다중특이성 항체 및 항체 약물 접합체(Biclonics®, Triclonics® 및 ADClonics®)를 전문으로 하는 생명공학 회사로, 24회 연례 니드햄 가상 의료 컨퍼런스에 참여한다고 발표했습니다.
회사의 회장 겸 CEO인 Bill Lundberg, M.D.는 2025년 4월 8일 화요일 오전 8:45 ET에 화상 대화에 참여할 예정입니다. 투자자 및 이해관계자는 Merus 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트에 접속할 수 있으며, 발표 녹화는 이벤트 이후 일정 기간 동안 이용 가능할 것입니다.
Merus N.V. (Nasdaq: MRUS), une entreprise biotechnologique spécialisée dans les anticorps multispecifiques innovants et les conjugués d'anticorps-médicaments (Biclonics®, Triclonics® et ADClonics®), a annoncé sa participation à la 24ème Conférence Virtuelle Annuelle de Needham sur la Santé.
Le Président et CEO de l'entreprise, Bill Lundberg, M.D., participera à une discussion informelle le mardi 8 avril 2025, à 8h45 ET. Les investisseurs et les parties intéressées peuvent accéder au webinaire en direct via la section Investisseurs du site web de Merus, où l'enregistrement de la présentation sera disponible pendant un certain temps après l'événement.
Merus N.V. (Nasdaq: MRUS), ein biotechnologisches Unternehmen, das sich auf innovative multispezifische Antikörper und Antikörper-Arzneimittel-Konjugate (Biclonics®, Triclonics® und ADClonics®) spezialisiert hat, hat seine Teilnahme an der 24. jährlichen virtuellen Needham Gesundheitskonferenz angekündigt.
Der Präsident und CEO des Unternehmens, Bill Lundberg, M.D., wird am Dienstag, den 8. April 2025, um 8:45 Uhr ET an einem informellen Gespräch teilnehmen. Investoren und Interessierte können über den Investorenbereich der Merus-Website auf das Live-Webcast zugreifen, wo die Präsentationsaufzeichnung für eine gewisse Zeit nach der Veranstaltung verfügbar bleibt.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.
Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.
Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl
FAQ
When is Merus (MRUS) presenting at the Needham Healthcare Conference 2025?
How can investors watch the Merus (MRUS) Needham Conference presentation?
What type of antibody technologies does Merus (MRUS) develop?
Who will represent Merus (MRUS) at the 2025 Needham Healthcare Conference?
